Boston Common Asset Management LLC Increases Position in Novo Nordisk A/S (NYSE:NVO)

Boston Common Asset Management LLC raised its stake in shares of Novo Nordisk A/S (NYSE:NVO) by 61.8% in the 1st quarter, HoldingsChannel.com reports. The firm owned 86,187 shares of the company’s stock after purchasing an additional 32,927 shares during the quarter. Boston Common Asset Management LLC’s holdings in Novo Nordisk A/S were worth $5,985,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of NVO. Nisa Investment Advisors LLC increased its position in Novo Nordisk A/S by 36.4% during the fourth quarter. Nisa Investment Advisors LLC now owns 1,500 shares of the company’s stock worth $129,000 after purchasing an additional 400 shares during the last quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management increased its position in Novo Nordisk A/S by 8.4% during the fourth quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management now owns 7,453 shares of the company’s stock worth $641,000 after purchasing an additional 578 shares during the last quarter. Union Bancaire Privee UBP SA acquired a new position in Novo Nordisk A/S during the fourth quarter worth approximately $746,000. Griffin Asset Management Inc. increased its position in Novo Nordisk A/S by 2.3% during the fourth quarter. Griffin Asset Management Inc. now owns 8,450 shares of the company’s stock worth $727,000 after purchasing an additional 190 shares during the last quarter. Finally, Revolve Wealth Partners LLC increased its position in Novo Nordisk A/S by 8.7% during the fourth quarter. Revolve Wealth Partners LLC now owns 2,490 shares of the company’s stock worth $214,000 after purchasing an additional 200 shares during the last quarter. Institutional investors and hedge funds own 11.54% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on NVO shares. Guggenheim lowered shares of Novo Nordisk A/S from a “strong-buy” rating to a “hold” rating in a research report on Thursday, April 17th. Stifel Nicolaus lowered shares of Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research report on Monday, March 3rd. BNP Paribas assumed coverage on shares of Novo Nordisk A/S in a research report on Tuesday, April 15th. They issued an “underperform” rating for the company. Hsbc Global Res raised shares of Novo Nordisk A/S to a “strong-buy” rating in a research report on Monday, April 28th. Finally, BMO Capital Markets reissued a “market perform” rating and issued a $64.00 price objective (down previously from $105.00) on shares of Novo Nordisk A/S in a research report on Thursday, April 17th. Two analysts have rated the stock with a sell rating, five have given a hold rating, five have assigned a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $135.00.

Novo Nordisk A/S Price Performance

NVO opened at $68.64 on Thursday. The company has a fifty day simple moving average of $65.74 and a 200 day simple moving average of $82.29. The firm has a market cap of $308.02 billion, a price-to-earnings ratio of 20.86, a PEG ratio of 0.90 and a beta of 0.65. Novo Nordisk A/S has a twelve month low of $57.00 and a twelve month high of $148.15. The company has a current ratio of 0.74, a quick ratio of 0.55 and a debt-to-equity ratio of 0.62.

Novo Nordisk A/S (NYSE:NVO) last released its quarterly earnings results on Wednesday, May 7th. The company reported $0.92 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.92. The business had revenue of $11.87 billion during the quarter. Novo Nordisk A/S had a net margin of 34.81% and a return on equity of 84.68%. Equities research analysts expect that Novo Nordisk A/S will post 3.84 EPS for the current fiscal year.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.